

# Ka Papp

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2182694/ka-papp-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

313  
papers

27,757  
citations

79  
h-index

162  
g-index

324  
ext. papers

32,125  
ext. citations

6.9  
avg, IF

6.79  
L-index

#	Paper	IF	Citations
313	Secukinumab in plaque psoriasis--results of two phase 3 trials. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 326-38	59.2	1319
312	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet, The</i> , <b>2008</b> , 371, 1665-74	40	1296
311	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). <i>Lancet, The</i> , <b>2008</b> , 371, 1675-84	40	1150
310	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <i>Lancet, The</i> , <b>2005</b> , 366, 1367-74	40	850
309	Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. <i>Lancet, The</i> , <b>2006</b> , 367, 29-35	40	832
308	Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1181-9	59.2	755
307	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 106-15	4.5	685
306	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1304-12	4	586
305	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , <b>2015</b> , 386, 541-51	40	576
304	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 389, 2287-2303	40	559
303	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1318-28	59.2	530
302	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 558-66	4	514
301	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 345-56	59.2	505
300	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 405-417	4.5	476
299	Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 976-86		467
298	Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 19057-62	11.5	382
297	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 56, 31.e1-15	4.5	370

296	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , <b>2016</b> , 387, 40-52	40	360
295	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, 37-49	4.5	360
294	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 422-34	59.2	324
293	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1551-1560	59.2	306
292	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <i>Lancet, The</i> , <b>2017</b> , 390, 276-288	40	302
291	Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 290, 3073-80	27.4	300
290	A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 47, 821-33	4.5	300
289	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 273-86	4	297
288	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 729-735	4.5	287
287	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 844-54	4	284
286	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , <b>2018</b> , 392, 650-661	40	283
285	European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 2277-94	4.6	271
284	Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 412-21	4	266
283	Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 902-911	4	263
282	Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. <i>Pediatrics</i> , <b>2002</b> , 110, e2	7.4	244
281	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 668-77	4	233
280	Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. <i>Journal of Allergy and Clinical Immunology</i> , <b>2002</b> , 110, 277-84	11.5	206
279	Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 380, 738-46	40	205

278	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 949-51	4.5	196
277	Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 425-33	4.5	191
276	Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of Drugs in Dermatology</i> , <b>2015</b> , 14, 706-14	2.2	187
275	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 930-9	4	186
274	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1313-1321	59.2	171
273	Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 1148-58	4.6	162
272	A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1586-96	59.2	158
271	A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 137-45	4	156
270	A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 1266-76	4	156
269	Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3156-67		151
268	Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2504-17		151
267	The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 45, 665-74	4.5	148
266	Biological therapies in the systemic management of psoriasis: International Consensus Conference. <i>British Journal of Dermatology</i> , <b>2004</b> , 151 Suppl 69, 3-17	4	139
265	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 1535-45	4.6	137
264	Dupilumab: A review of its use in the treatment of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, S28-S36	4.5	135
263	Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 48, 48-54	4.5	134
262	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 241-51	4.5	129
261	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 877-884	11.5	129

260	A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 304-14	4.3	128
259	Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. <i>Experimental Dermatology</i> , <b>2015</b> , 24, 529-35	4	123
258	Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. <i>Wound Repair and Regeneration</i> , <b>2000</b> , 8, 162-8	3.6	123
257	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 44, 643-51	4.5	117
256	Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 549-57	4	115
255	Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. <i>British Journal of Dermatology</i> , <b>2004</b> , 150, 96-102	4	113
254	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , <b>2018</b> , 391, 2213-2224	4.0	113
253	Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 310-317.e1	4.5	110
252	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 841-50	4.5	108
251	Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 2466-2469	4.3	107
250	CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. <i>British Journal of Dermatology</i> , <b>2006</b> , 155, 170-81	4	107
249	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 277-286.e10	4.5	105
248	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 742-51	4.5	105
247	Relapse, rebound, and psoriasis adverse events: an advisory group report. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S171-81	4.5	104
246	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 81-89.e5	4.5	95
245	A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 649-57	4	95
244	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 861-72	4	95
243	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 571-9	4.5	92

242	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , <b>2006</b> , 154, 1161-8	4	92
241	Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. <i>British Journal of Dermatology</i> , <b>2007</b> , 157, 1275-4	4	90
240	Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. <i>Pediatrics</i> , <b>2006</b> , 117, e118-28	7.4	90
239	Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 1183-1190.e3	4.5	88
238	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 432-440.e17	4.5	88
237	European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1951-1963	4.6	86
236	Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 240-6	4.5	85
235	Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 271-82	4.6	79
234	Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 434-41	4	79
233	Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 429-36		77
232	Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 137-46	4	76
231	Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 572-582	11.5	75
230	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 1093-1102	4.5	74
229	The long-term efficacy and safety of new biological therapies for psoriasis. <i>Archives of Dermatological Research</i> , <b>2006</b> , 298, 7-15	3.3	74
228	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 40-49	4.0	73
227	A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2006</b> , 9 Suppl 1, 10-7	1.6	72
226	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, e33-45	4.5	69
225	Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 992-9	4	69

224	A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 767-76	4	68
223	Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. <i>Lancet, The</i> , <b>2008</b> , 371, 1337-42	4.0	67
222	Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 208, 1391-6	7	66
221	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 77-82.e7	4.5	65
220	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 671-81	4.5	64
219	Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 247-53	4.5	64
218	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 649-658	5.1	62
217	A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 427-36	4.5	62
216	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. <i>International Journal of Dermatology</i> , <b>2006</b> , 45, 605-14	1.7	61
215	Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group. <i>Dermatology</i> , <b>2000</b> , 200, 17-24	4.4	61
214	The incidence of cancer associated with the treatment of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>1999</b> , 29, 148-58	5.3	61
213	Canadian guidelines for the management of plaque psoriasis: overview. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2011</b> , 15, 210-9	1.6	60
212	An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1912-21	3.5	60
211	Efalizumab for the treatment of psoriatic arthritis. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2007</b> , 11, 57-66	1.6	58
210	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1348-1358	4	58
209	The psychosocial impact of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, S19-22	4.5	57
208	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 674-681	4	57
207	PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. <i>Journal of Drugs in Dermatology</i> , <b>2012</b> , 11, 1210-7	2.2	57

206	Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 67, 245-56	4.5	56
205	Scalp psoriasis: a review of current topical treatment options. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2007</b> , 21, 1151-60	4.6	54
204	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , <b>2016</b> , 16, 15	2.1	51
203	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 487-498	4.0	51
202	Management of egfr tki-induced dermatologic adverse events. <i>Current Oncology</i> , <b>2015</b> , 22, 123-32	2.8	50
201	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, 410-9.e6	4.5	49
200	The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. <i>American Journal of Clinical Dermatology</i> , <b>2011</b> , 12, 321-37	7.1	49
199	Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. <i>Journal of Drugs in Dermatology</i> , <b>2004</b> , 3, 27-38	2.2	49
198	Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 1111-1119	4.6	47
197	Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 1252-61	4.6	47
196	A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, 472-8	4.5	47
195	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1562-1574	4	46
194	An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. <i>Journal of Drugs in Dermatology</i> , <b>2012</b> , 11, 300-12	2.2	45
193	Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 90-99.e1	4.5	44
192	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 83-8	2.4	44
191	Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. <i>Dermatology</i> , <b>2011</b> , 222, 148-56	4.4	43
190	Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 88-95	4	42
189	Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. <i>Dermatology</i> , <b>2010</b> , 221, 172-8	4.4	42



188	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1039-1049	4	41
187	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1004-1013	4.6	40
186	Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. <i>Health and Quality of Life Outcomes</i> , <b>2013</b> , 11, 82	3	40
185	Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 231-241	4	40
184	Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1305-1313	4.5	39
183	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 615-622	4	39
182	Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 634-42	4.6	39
181	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 436-439	4.5	39
180	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S112-9	4.5	38
179	Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2004</b> , 8, 321-337	1.6	38
178	Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1296-303	4	38
177	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 936-945	4.5	38
176	Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 320-328	4	36
175	Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 1315-1323	4	36
174	Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1234-43	4.1	36
173	Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. <i>BioDrugs</i> , <b>2015</b> , 29, 327-39	7.9	35
172	Review of Systemic Treatment Options for Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2017</b> , 21, 31-39	1.6	35
171	A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2016</b> , 20, 44-51	1.6	32

170	Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 372-374	4.5	32
169	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1537-1551	4	31
168	A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. <i>International Journal of Dermatology</i> , <b>2010</b> , 49, 1368-75	1.7	30
167	A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 407-12	4	30
166	Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S164-70	4.5	30
165	Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. <i>International Journal of Dermatology</i> , <b>2004</b> , 43, 978-83	1.7	29
164	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 133-150	4	29
163	Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 863-872	4.5	29
162	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1367-1374	4.5	28
161	A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. <i>Vaccine</i> , <b>2011</b> , 29, 1921-8	4.1	28
160	Analytical approaches to reporting long-term clinical trial data. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 2001-8	2.5	28
159	Long-term management of plaque psoriasis with continuous efalizumab therapy. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S182-8	4.5	28
158	IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. <i>Lancet, The</i> , <b>2021</b> , 397, 1564-1575	4.0	28
157	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 130-141	4.2	28
156	A Review of Psoriasis, Therapies, and Suicide. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2016</b> , 20, 293-303	3.5	28
155	Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , <b>2018</b> , 5, 567-582	4.4	28
154	Psoriasis: consensus on topical therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2008</b> , 22, 859-70	4.6	27
153	Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 62-70	4.5	27

152	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , <b>2017</b> , 18, 273-280	7.1	26
151	Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. <i>BMC Dermatology</i> , <b>2015</b> , 15, 8	2.1	26
150	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , <b>2018</b> , 17, 826-832	2.2	26
149	Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 67, e11-5	4.5	25
148	Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1876-1883	4.6	24
147	Leprotic involvement of peripheral nerves in the absence of skin lesions. Case report and literature review. <i>Journal of the American Academy of Dermatology</i> , <b>1990</b> , 23, 1023-6	4.5	24
146	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 1047-1058	4	24
145	Biologic therapy in psoriasis: perspectives on associated risks and patient management. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2012</b> , 16, 153-68	1.6	23
144	Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2004</b> , 8, 321-37	1.6	23
143	Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2005</b> , 9, 303-12	1.6	23
142	Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. <i>Rheumatology</i> , <b>2020</b> , 59, 3834-3844	3.9	23
141	Trial of Roflumilast Cream for Chronic Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 229-239	3.9	23
140	Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 1174-1182	11.6	22
139	Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2005</b> , 9, 303-312	1.6	22
138	Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1352-1360	4	22
137	AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 316-326	4	22
136	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 431-447	4	21
135	Epidemiology and quality of life of patients with psoriasis in Chile. <i>Actas Dermo-sifiligráficas</i> , <b>2011</b> , 102, 810-6	0.5	21

134	Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2005</b> , 9, 313-23	1.6	21
133	Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , <b>2016</b> , 17, 79-86	7.1	20
132	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. <i>American Journal of Clinical Dermatology</i> , <b>2019</b> , 20, 863-871	7.1	19
131	Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis. <i>Biopharmaceutics and Drug Disposition</i> , <b>2018</b> , 39, 245-255	1.7	19
130	A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2009</b> , 13, 294-302	1.6	19
129	Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 1177-1189	4	18
128	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1269-1277	4.5	18
127	Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28, 790-8	4.6	17
126	Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2010</b> , 21, 185-92	2.8	17
125	Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial. <i>Journal of Dermatology</i> , <b>2017</b> , 44, 1228-1237	1.6	16
124	Managing cardiovascular risk in patients with chronic inflammatory diseases. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 585-94	3.9	16
123	Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. <i>International Journal of Dermatology</i> , <b>2010</b> , 49, 818-28	1.7	16
122	Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial. <i>Psoriasis Forum</i> , <b>2007</b> , 13a, 4-11		16
121	Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2002</b> , 6, 529-34	1.6	16
120	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. <i>American Journal of Clinical Dermatology</i> , <b>2019</b> , 20, 155-164	7.1	16
119	Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials. <i>Journal of Drugs in Dermatology</i> , <b>2016</b> , 15, 568-80	2.2	16
118	Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 2305-2312	4.6	15
117	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 76-85	4	15

116	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 519-534	4.1	14
115	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 751-754	4.1	14
114	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 1098-1106	4.6	14
113	Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2010</b> , 14, 167-74	1.6	14
112	Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. <i>BMC Dermatology</i> , <b>2007</b> , 7, 2	2.1	14
111	Systemic gold therapy. <i>Clinics in Dermatology</i> , <b>1991</b> , 9, 535-51	3	14
110	The safety of etanercept for the treatment of plaque psoriasis. <i>Therapeutics and Clinical Risk Management</i> , <b>2007</b> , 3, 245-58	2.9	14
109	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1359-1368	4	14
108	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 180-189	4	14
107	Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26, 1007-13	4.6	13
106	Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. <i>Archives of Dermatological Research</i> , <b>2009</b> , 301, 429-42	3.3	13
105	Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2008</b> , 12 Suppl 1, S1-10	1.6	13
104	Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2[5]-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 889-899	4	13
103	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2018</b> , 22, 10S-16S	1.6	13
102	Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1324-1332	4.6	12
101	Etanercept in psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2004</b> , 5, 2139-46	4	12
100	Efficacy and safety of etanercept in patients with psoriasis: results of a global phase iii study. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, P159	4.5	12
99	Diagnosis and Management of Conjunctivitis for the Dermatologist. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2018</b> , 22, 200-206	1.6	12

98	Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2009</b> , 13 Suppl 2, S58-66	1.6	11
97	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-9	2.8	11
96	Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 1037-1048	4	11
95	Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2017</b> , 6, 322-330	4.5	10
94	A Randomized, blinded assessor study to Evaluate the efficacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 361-366	4.6	10
93	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 1515-1522	4.6	10
92	Disease characteristics in patients with and without psoriatic arthritis treated with etanercept. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28, 581-9	4.6	10
91	Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPSAKE 1 trial.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
90	Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. <i>European Journal of Dermatology</i> , <b>2010</b> , 20, 585-9	0.8	10
89	Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2020</b> , 24, 3S-14S	1.6	9
88	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2018</b> , 22, 78-83	1.6	9
87	Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 2287-300	2.5	9
86	Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2011</b> , 15, 309-21	1.6	9
85	Long-term efficacy of up to 15 months of efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis. <i>Dermatologic Therapy</i> , <b>2008</b> , 21 Suppl 3, S6-14	2.2	9
84	Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. <i>BMC Dermatology</i> , <b>2006</b> , 6, 9	2.1	9
83	Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 1423-1433	3.8	9
82	Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 411-418	4	8
81	Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. <i>Value in Health</i> , <b>2018</b> , 21, 1-8	3.3	8

80	Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2005</b> , 9, 276-83	1.6	8
79	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 2219-2229	5.2	8
78	A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 1513-1515	4.3	8
77	Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2018</b> , 22, 38-43	1.6	7
76	Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. <i>Clinical Drug Investigation</i> , <b>2011</b> , 31, 51-60	3.2	7
75	Evaluation of efalizumab using safe psoriasis control. <i>BMC Dermatology</i> , <b>2006</b> , 6, 8	2.1	7
74	Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2006</b> , 9 Suppl 1, 18-25	1.6	7
73	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	7
72	Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1302-1308	4.6	7
71	Psoriasis Prevalence and Severity by Expert Elicitation. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1053-1064	4	7
70	Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	7
69	Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2013</b> , 17, 89-105	1.6	6
68	Psoriasis care: new and emerging pharmacologic trends. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2010</b> , 14, 119-29	1.6	6
67	Update on alefacept safety. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2009</b> , 13 Suppl 3, S139-47	1.6	6
66	Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial. <i>Drug Safety</i> , <b>2008</b> , 31, 715-26	5.1	6
65	Potential future therapies for psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2005</b> , 24, 58-63	1.4	6
64	Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2006</b> , 9 Suppl 1, 26-32	1.6	6
63	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.. <i>Dermatology and Therapy</i> , <b>2022</b> , 12, 495	4	6

62	Secukinumab: Review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2016</b> , 9, S7-S12	1.2	6
61	Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPSAKE 2 trial. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	6
60	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2017</b> , 21, 2S-40S	1.6	5
59	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2809-2820	4.6	5
58	Clinical Trial and Registry Data. <i>Current Problems in Dermatology</i> , <b>2018</b> , 53, 15-27		5
57	Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26, 1407-14	4.6	5
56	The AWARE study: methodology and baseline characteristics. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2009</b> , 13 Suppl 3, S113-21	1.6	5
55	Neoral <sup>®</sup> in the Treatment of Psoriasis: Consensus Treatment Guidelines. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>1997</b> , 1, 209-215	1.6	5
54	Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator. <i>Drugs of Today</i> , <b>2004</b> , 40, 889-99		5
53	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 797-806	4.6	5
52	Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 1152-1160	4.6	5
51	Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2020</b> , 24, 561-572	1.6	4
50	Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. <i>Allergy, Asthma and Clinical Immunology</i> , <b>2017</b> , 13, 38	3.2	4
49	Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 1555-61	4.6	4
48	Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2013</b> , 2, 44	4.5	4
47	Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2009</b> , 13 Suppl 3, S131-8	1.6	4
46	Monitoring biologics for the treatment of psoriasis. <i>Clinics in Dermatology</i> , <b>2008</b> , 26, 515-21	3	4
45	Pimecrolimus cream 1% provides effective long-term control of atopic dermatitis in infants. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, P65	4.5	4



44	Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2005</b> , 9, 313-323	1.6	4
43	Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician. <i>Canadian Family Physician</i> , <b>2012</b> , 58, e390-400	0.9	4
42	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	4
41	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. <i>Journal of the American Association of Nurse Practitioners</i> , <b>2018</b> , 30, 529-541	1	4
40	Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 2431-2439	4.6	4
39	Treating to Target(s) With Interleukin-17 Inhibitors. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2019</b> , 23, 3S-34S	1.6	3
38	Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 593-595	4.5	3
37	Ixekizumab for psoriasis--AuthorsQeplly. <i>Lancet, The</i> , <b>2016</b> , 387, 226-7	4.0	3
36	Practical guidelines for the long-term treatment of psoriasis with efalizumab. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S153	4.5	3
35	Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, P157	4.5	3
34	Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. <i>BMC Dermatology</i> , <b>2019</b> , 19, 9	2.1	2
33	IxekizumabAn Effective and Safe Treatment for Moderate-to-Severe Plaque Psoriasis in Patients Previously Treated With Other IL-17 Inhibitors: Results From IXORA-P. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2019</b> , 4, 180-185	1.1	2
32	Comment on "Quantitative Evaluation ofBiologic Therapy Options for Psoriasis: ASystematic Review and Network Meta-Analysis". <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 2642-2644	4.3	2
31	Preparing for subsequent entry biologics in dermatology and rheumatology in Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2013</b> , 17, 340-6	1.6	2
30	Monitoring patients treated with efalizumab or alefacept. <i>Current Problems in Dermatology</i> , <b>2009</b> , 38, 95-106		2
29	Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. <i>Journal of Dermatology</i> , <b>2021</b> ,	1.6	2
28	An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static PhysicianQ GlobalAssessment > 1 at week 12. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 52-59	4	2
27	OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2018</b> , 22, 297-303	1.6	1

26	Long-term, continuous dosing of etanercept in patients with plaque psoriasis. <i>Expert Review of Dermatology</i> , <b>2011</b> , 6, 361-373		1
25	Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2007</b> , 11, S3-S13	1.6	1
24	Long-Term Safety of Etanercept. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2007</b> , 11, S23-S36	1.6	1
23	Effects of Risankizumab on Nail Psoriasis in Patients with Active Psoriatic Arthritis: Results from KEEPsAKE-1.. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2022</b> ,	4.6	1
22	Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 911-917	5.9	1
21	Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1291-1304	4	1
20	Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	1
19	Predictors of Topical Use in Psoriasis Patients in the REFINE Study. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2016</b> , 20, 106-12	1.6	1
18	Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-8	2.8	1
17	Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. <i>International Journal of Dermatology</i> , <b>2021</b> ,	1.7	1
16	Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	1
15	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology.. <i>Dermatology and Therapy</i> , <b>2021</b> , 12, 253	4	1
14	Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	0
13	Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 840-842	4	0
12	Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1657-1665	4	0
11	Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e15104	2.2	0
10	Practical Management of Patients with Atopic Dermatitis on Dupilumab. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1805-1828	4	0
9	Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 487-497	4	0

8	Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2022</b> , 12034754221088584	1.6	o
7	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.. <i>Dermatology and Therapy</i> , <b>2022</b> , 12, 1073	4	o
6	Response to Psoriasis patients' preference for an aerosol foam topical formulation by Vender R et al. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, e401-e402	4.6	
5	An Open Letter to Health Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2017</b> , 21, 195-196	1.6	
4	Understanding and assessing potential serious adverse events: a practical approach to understanding the benefits and harm of psoriasis treatments. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2013</b> , 17, 189-96	1.6	
3	Voclosporin (ISA247) for plaque psoriasis [Authors' reply]. <i>Lancet, The</i> , <b>2008</b> , 372, 889	4	o
2	Etanercept: A Novel Tumor Necrosis Factor Antagonist for the Treatment of Psoriatic Disease. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2007</b> , 11, S1-S2	1.6	
1	The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.. <i>British Journal of Dermatology</i> , <b>2022</b> ,	4	